Marker Therapeutics (MRKR) Convertible Debt (2011 - 2014)
Marker Therapeutics (MRKR) reported Convertible Debt of $52942.0 for Q4 2014, down 90.68% quarter-over-quarter from $568127.0 in Q3 2011.
Marker Therapeutics (MRKR) Convertible Debt (2011 - 2014) Analysis & Trends
Marker Therapeutics (MRKR) has 2 years of Convertible Debt data on file, last reported at $52942.0 in Q4 2014.
- Convertible Debt for Q4 2014 came in at $52942.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2014 was $52942.0 (changed N/A YoY), and the FY2014 annual result was $52942.0, changed N/A from the prior year.
- Convertible Debt slipped to $52942.0 in Q4 2014 per MRKR's latest filing, from $568127.0 in the prior quarter.
- Over five years, Convertible Debt peaked at $568127.0 in Q3 2011 and troughed at $52942.0 in Q4 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Marker Therapeutics | 28.20 Mn | 28.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2014 | 52,942.00 |
| Sep 30, 2011 | 568,127.00 |
| Jun 30, 2011 | 504,469.00 |